CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5) Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Heart Failure With Preserved Ejection Fraction in the Young Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Review ArticleVolume 7, Issue 12, December 2019

JOURNAL:JACC: Heart Failure Article Link

Frailty Is Intertwined With Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management

A Pandey, D Kitzman, G Reeves. Keywords: aging; frailty; Fried phenotype; heart failure; physical function; quality of life

ABSTRACT

Frailty, a syndrome characterized by an exaggerated decline in function and reserve of multiple physiological systems, is common in older patients with heart failure (HF) and is associated with worse clinical and patient-reported outcomes. Although several detailed assessment tools have been developed and validated in the geriatric population, they are cumbersome, not validated in patients with HF, and not commonly used in routine management of patients with HF. More recently, there has been an increasing interest in developing simple frailty screening tools that could efficiently and quickly identify frail patients with HF in routine clinical settings. As the burden and recognition of frailty in older patients with HF increase, a more comprehensive approach to management is needed that targets deficits across multiple domains, including physical function and medical, cognitive, and social domains. Such a multidomain approach is critical to address the unique, multidimensional challenges to the care of these high-risk patients and to improve their functional status, quality of life, and long-term clinical outcomes. This review discusses the burden of frailty, the conceptual underpinnings of frailty in older patients with HF, and potential strategies for the assessment, screening, and management of frailty in this vulnerable patient population.